Axsome Therapeutics, Inc. (AXSM) Stock
AXSM has an Alpha Score of 12 out of 100 (poor), computed on Nov 11, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 1 trade in AXSM since 2022: 1 purchase and 0 sales, most recently Christopher L. Jacobs (purchase, Jun 16, 2022). 8 of the hedge funds AlphaScala tracks reported AXSM in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $148.03M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 10, 2026.
What is AXSM's Alpha Score?
How it works →Alpha Score of 12 reflects poor overall profile with poor momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 11, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Axsome Therapeutics, Inc. (AXSM)?
Most recent: Christopher L. Jacobs (purchase, Jun 16, 2022); records start Jun 16, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Chris Jacobs R-NY · House | 2022-06-16 | purchase | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 9, 2026.
See all AXSM political trades →Which hedge funds own AXSM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 605K | $148.03M | +0% |
| Millennium Management Israel Englander | 556K | $136.11M | +2579% |
| Point72 Steve Cohen | 417K | $101.95M | -2% |
| Renaissance Technologies Jim Simons (founder) | 262K | $64.13M | +59% |
| Citadel Ken Griffin | 256K | $62.63M | -9% |
| Marshall Wace | 223K | $54.68M | +58% |
| Bridgewater Associates Ray Dalio | 58K | $14.25M | +2% |
| Hussman Investment Trust John Hussman | 4K | $774.4K | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Axsome Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 3, 26 | Jacobson Mark L. | Chief Operating Officer | SELL | 10.0K | $2.1M |
| Aug 6, 26 | Tabuteau Herriot | Chief Executive Officer | SELL | 4.7K | $997K |
| Aug 5, 26 | Tabuteau Herriot | Chief Executive Officer | SELL | 45.0K | $9.5M |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are AXSM's key statistics?
Key statistics as of Nov 3, 2026
How does AXSM's valuation compare with the Healthcare sector?
| Metric | AXSM | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -24.68% | 3.60% | 175 |
| Return on equity | -255.60% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
AXSM price chart
Powered by TradingViewWhat does Axsome Therapeutics, Inc. do?
Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous system disorders. The company focuses on conditions with limited treatment options, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome's approach includes fixed-dose combinations and reformulations designed to deliver differentiated therapeutic solutions. The company maintains a pipeline of clinical-stage CNS therapies addressing significant and growing markets. Founded in 2012 and headquartered in New York, New York, Axsome operates as a single business segment dedicated to developing and delivering innovative treatments for patients with underserved CNS conditions. The company has transitioned to commercializing its marketed products while advancing its pipeline of differentiated therapeutic candidates.